<DOC>
	<DOCNO>NCT00338039</DOCNO>
	<brief_summary>The primary objective evaluate efficacy combination cetuximab systemic chemotherapy follow chemoradiation locally advanced pancreatic cancer . The primary endpoint actuarial one-year survival . The secondary objective : - To evaluate local tumor response patient treat regimen . - To characterize safety regimen .</brief_summary>
	<brief_title>Induction Cetuximab ( IM-C225 ) , Gemcitabine , Oxaliplatin Pancreatic Cancer Patients</brief_title>
	<detailed_description>Cetuximab drug block epidermal growth factor receptor ( EGFR ) . EGFR may involve certain type cancer . When EGFR stimulate , series chemical reaction start result tumor `` tell '' grow . Cetuximab try stop reaction block EGFR . This may stop tumor grow . Cetuximab show increase effect chemotherapy radiation therapy , also give study . Before start treatment study , call `` screening test . '' These test help doctor decide eligible take part study . You complete medical history physical exam . Blood ( 2 tablespoon ) urine collect routine test . Chest x-rays compute tomography ( CT ) scan abdomen do . Women able child must negative urine pregnancy test . If find eligible take part study , first receive cetuximab every 2 week 8 week ( 4 dos ) . Cetuximab give every 2 week throughout duration study . Cetuximab continue radiation capecitabine combination , retesting stage chemotherapy give radiation therapy . Cetuximab infusion give approximately 2 hour . Gemcitabine oxaliplatin chemotherapy give every 2 week ( 4 dos ) 8 week . Both drug give central line 2 hour . Cetuximab give first , follow gemcitabine , follow oxaliplatin . A CT scan chest X-ray do 2 week last dose ( Week 10 ) . As long tumor grow spread , receive cetuximab , capecitabine , radiation therapy together . The Capecitabine give mouth twice day every day radiation therapy ( 5 1/2 week ) . Radiation therapy give day 5 day row . It give 5 1/2 week 28 treatment . The radiation give 4 direction focus tumor lie back . You continue receive cetuximab vein every 2 week capecitabine radiation therapy . After radiotherapy , continue take cetuximab vein every 2 week . The effect treatment evaluate 5-6 week completion radiation therapy capecitabine . A chest x-ray CT scan perform , 2 tablespoon blood drawn routine testing . As long tumor grow spread side effect severe , may continue receive Cetuximab vein every 2 week . You also receive Gemcitabine vein dose 3 every 4 week long tumor grow side effect severe . CT scan chest x-rays do every 2 month evaluate status tumor . During study , physical exam , include weekly blood test ( 2 tablespoon ) . The possible development side effect closely monitor could require extra blood and/or urine sample . You take study disease get bad intolerable side effect occur . You may surgery time therapy tumor remove surgically . A separate consent form use situation . This investigational study . Capecitabine , oxaliplatin , cetuximab approve FDA colon cancer approve FDA pancreatic cancer . Up 69 patient take part multicenter study . Up 60 enrol M. D. Anderson .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Cytologic histologic proof adenocarcinoma pancreas require prior treatment . Patients tumor originate part pancreas . Islet cell tumor eligible . Only patient non metastatic , unresectable disease ( AJCC 2002 stage T4 NX M0 ) eligible . Computed Tomography ( CT ) finding lung , liver , peritoneal metastasis equivocal , eligible . Patients undergo resection underlie medical problem also eligible . Diagnosis Pancreatic Adenocarcinoma bile duce brushing acceptable . Patients regional nodal disease eligible . 2 . All patient must stag physical exam , chest Xray ( CXR ) , contrastenhanced helical thincut abdominal CT. Unresectability define CT criterion : ) evidence tumor extension celiac axis superior mesenteric ( SM ) artery , b ) evidence either CT angiogram occlusion SM vein SM/ portal vein confluence . If tumor meet definition find unresectable surgical exploration , tumor consider unresectable . 3 . Patients must 18 year old . There upper age restriction 4 . Karnofsky performance status great equal 70 eligible . 5 . Patients must either child bear potential negative urine pregnancy test within 72 hour treatment . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal least 12 month . 6 . Women childbearing potential must agree practice adequate contraception refrain breastfeeding , specify informed consent . Sexually active male must practice contraception study . 7 . Bone marrow function : absolute neutrophil count ( ANC ) &gt; 1,500/ul . Platelets &gt; 100,000/ul . 8 . Renal function : creatinine clearance &gt; 30 mL/min ( calculate CockcroftGault equation ) . 9 . Hepatic function : Total bilirubin less 5mg/dL . If patient require endobiliary stent , bilirubin level must decline consecutive measurement indicate adequate biliary decompression ; alanine aminotransferase ( ALT ) less equal 5 time upper limit normal . 10 . Neurologic function : neuropathy ( sensory ) &lt; Common Toxicity Criteria ( CTC ) Grade 2 . 11 . Patients must sign studyspecific consent form , attach protocol . 1 . Patients history prior metastatic cancer . 2 . Patients must significant infection , i.e. , require intravenous ( IV ) antibiotic , coexistent medical condition would preclude protocol therapy . 3 . Significant history uncontrolled cardiac disease ; i.e. , uncontrolled hypertension , unstable angina , recent myocardial infarction ( within prior 6 month ) , uncontrolled congestive heart failure , cardiomyopathy ejection fraction less &lt; 30 % . 4 . Prior therapy specifically directly target estimate EGFR pathway . 5 . Prior severe infusion reaction ( bronchospasm , stridor , urticaria and/or hypotension ) monoclonal antibody . 6 . Any prior history radiotherapy abdomen . 7 . History evidence upon physical examination central nervous system ( CNS ) disease ( e.g. , primary brain tumor , seizures control standard medical therapy , brain metastasis , history stroke ) 8 . Prior unanticipated severe reaction fluoropyrimidine therapy know hypersensitivity 5fluorouracil . 9 . Patients organ allograft . 10 . Patients Coumadin must change Lovenox least 1 week prior start capecitabine . Low dose ( 1 mg ) Coumadin allow . 11 . Patients take Sorivudine Brivudine A must drug 4 week prior start capecitabine . Patients take cimetidine must drug discontinue . Ranitidine drug another antiulcer class substitute cimetidine necessary .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>C225</keyword>
	<keyword>Erbitux</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Eloxatin</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
</DOC>